SI-BONE Q2 revenue $33.3M (+30% YoY); raises FY 2023 revenue guidance to $132-134M

SI-BONE, Inc.

2023-Q2 EPS reported -$0.61 revenue$66,013,000

Record worldwide revenue $33.3M (+30% YoY); U.S. revenue $31.2M (+31% YoY).
Net loss improved to $11.2M ($0.30 diluted loss) from $18.5M ($0.54) in Q2 2022.
Adjusted EBITDA loss narrowed 59% to -$4.7M from -$11.5M.
FY 2023 revenue guidance raised to $132-134M (prior $128-131M), implying 24-26% growth.
Gross margin 81% vs 86% a year ago, impacted by product mix and higher depreciation.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SI-BONE, Inc. reported the quarter ended June 30, 2023 results: revenue $33.3 million, net income $11.2 million, or $0.30 per diluted share, EPS $0.30 per diluted share. Guidance raised.

Period: the quarter ended June 30, 2023
Revenue: $33.3 million
Net income: $11.2 million, or $0.30 per diluted share
EPS: $0.30 per diluted share
Guidance: raised
Result: reported results

Exact text from the filing

musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended June 30, 2023. Recent Highlights • Record worldwide revenue of $33.3 million for the second quarter 2023, representing approximately 30% growth over the corresponding period in 2022 • Record U.S. revenue of $31.2 million for the second quarter 2023,

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

SI-BONE, Inc. filing history →

Source: SEC EDGAR

accession 0001459839-23-000088

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.